

**CORTICOSTEROID THERAPY IN
DIFFUSE DIABETIC MACULAR
EDEMA CLINICAL OUTCOMES,
SPECTRAL OCT FINDINGS,
AND LESSONS FOR CURRENT
PRACTICE**

Hasan Burhanettin KAPTI
Ordu University



© Copyright 2026

Printing, broadcasting and sales rights of this book are reserved to Academician Bookstore House Inc. All or parts of this book may not be reproduced, printed or distributed by any means mechanical, electronic, photocopying, magnetic paper and/or other methods without prior written permission of the publisher. Tables, figures and graphics cannot be used for commercial purposes without permission. This book is sold with banderol of Republic of Türkiye Ministry of Culture.

**This book is derived from the postgraduate specialty thesis "Diffüz Diabetik Maküla Ödeminde Intravitreal Triamsinolon Asetonid Enjeksiyonunun Klinik Sonuçları ve Spectral OCT Bulguları" (Thesis Registration No. 736206), Trabzon Numune Training and Research Hospital, Department of Ophthalmology, 2010, supervised by Prof. Dr. Kubilay Çetinkaya.*

ISBN 978-625-362-237-4	Page and Cover Design Typesetting and Cover Design by Akademisyen
Book Title Corticosteroid Therapy In Diffuse Diabetic Macular Edema Clinical Outcomes, Spectral Oct Findings, And Lessons For Current Practice	Publisher Certificate Number 47518
Editor Kubilay ÇETİNKAYA	Printing and Binding Vadi Printingpress
Author Hasan Burhanettin KAPTI ORCID iD: 0000-0002-3960-654	Bisac Code MED085100
Publishing Coordinator Yasin DİLMEN	DOI 10.37609/akya.4353

Library ID Card

Kaptı, Hasan Burhanettin.

Corticosteroid Therapy In Diffuse Diabetic Macular Edema Clinical Outcomes, Spectral Oct Findings, And Lessons For Current Practice / Hasan Burhanettin Kaptı, ed; Kubilay Çetinkaya.

Ankara : Akademisyen Yayınevi Kitabevi, 2026.

57 p. ; 135x210 mm.

Includes References.

ISBN 9786253622374

WARNING

The information contained in this product is only presented as a source for licensed medical workers. It should not be used for any professional medical advice or medical diagnosis. It does not constitute a doctor-patient, therapist-patient and / or any other health-presentation service relationship between the Bookstore and the recipient in any way.

This product is not a synonym or a substitute for professional medical decisions. The Academician Bookstore and its affiliated companies, writers, participants, partners and sponsors are not responsible for injuries and / or damage to humans and devices arising from all applications based on product information.

In the case of prescription of drugs or other chemicals, checking over the current product information for each drug defined by the manufacturer to determine the recommended dose, duration, method and contraindications of the drug is recommended.

It is the physician's own responsibility to determine the optimal treatment an dose for the patient, and to establish a basis for the knowledge and experience of the treating physician about the patient.

The Academician Bookstore is not responsible for any changes to the product, repackaging and customizations made by a third party.

GENERAL DISTRIBUTION

Akademisyen Yayınevi

Halk Sokak 5 / A Yenışehir / Ankara

Tel: 0312 431 16 33

siparis@akademisyen.com

www.akademisyen.com

CONTENTS

CHAPTER 1

INTRODUCTION	1
--------------------	---

CHAPTER 2

GENERAL INFORMATION	3
2.1 Retinal Anatomy	3
2.2 Macular Anatomy	5
2.3 Diabetic Retinopathy	8
2.3.1 Etiology and Pathogenesis	8
2.3.2 Risk Factors	11
2.3.3 Classification of Diabetic Retinopathy	13
2.3.4 Pathogenesis of Diabetic Macular Edema	15
2.3.5 Ancillary Diagnostic Methods in Diabetic Macular Edema	18
2.3.6 Treatment of Diabetic Macular Edema	21

CHAPTER 3

MATERIALS AND METHODS	29
-----------------------------	----

CHAPTER 4

RESULTS	33
---------------	----

CHAPTER 5

DISCUSSION AND CONCLUSION	37
---------------------------------	----

REFERENCES	45
------------------	----

REFERENCES

1. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. *Neurology*. 1993;43(4):817-824.
2. Leibowitz HM, Krueger DE, Maunders LR, et al. The Framingham Eye Study Monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of adults. *Survey of Ophthalmology*. 1980;24(Suppl):335-610.
3. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XIV: ten-year incidence and progression of diabetic retinopathy. *Archives of Ophthalmology*. 1994;112(9):1217-1228.
4. Ferris FL 3rd, Patz A. Macular edema: a complication of diabetic retinopathy. *Survey of Ophthalmology*. 1984;28(Suppl):452-461.
5. Hikichi T, Fujio N, Akiba J, Azuma Y, et al. Association between the short-term natural history of diabetic macular edema and the vitreomacular relationship. *Ophthalmology*. 1997;104(3):473-478.
6. Stern AL, Taylor DM, Dalburg LA, Cosentino RT. Pseudophakic cystoid maculopathy: a study of 50 cases. *Ophthalmology*. 1981;88(9):942-946.
7. Bengisu Ü. *Göz Hastalıkları*. Ankara: Palme Yayıncılık; 1989:161-166.
8. Tasman W, Jaeger EA, Rullo C, Montzka D, Zacierka MD. *Duane's Clinical Ophthalmology*. Philadelphia: JB Lippincott Company; 1994.
9. Albert DM, Jakobiec FA, eds. *Principles and Practice of Ophthalmology*. Philadelphia: WB Saunders Company; 1994.
10. Yanoff M, Duker JS. *Ophthalmology*. 2nd ed. St. Louis: Mosby; 2004.
11. Flynn HW Jr, et al. *Basic and Clinical Science Course, Section 12: Retina and Vitreous*. San Francisco: American Academy of Ophthalmology; 2003-2004.
12. Williams PL, Warwick R. *Gray's Anatomy*. London: Churchill Livingstone; 1980:1163-1176.
13. Aydın P, Akova YA. *Göz Hastalıkları*. Ankara: Güneş Kitabevi; 2001:34-35.
14. Aydın P, Akova YA. *Göz Hastalıkları*. Ankara: Güneş Kitabevi; 2001:15-18.
15. American Academy of Ophthalmology. *The Eye: Fundamentals and Principles of Ophthalmology, Section II*. San Francisco: LEO; 2000:68-88.
16. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. *Neurology*. 1993;43(4):817-824.
17. Apaydın C. Anatomi. In: Aydın P, Akova YA, eds. *Temel Göz Hastalıkları*. Ankara: Güneş Kitabevi; 2001:18.

18. Frank RN. On the pathogenesis of diabetic retinopathy. *Ophthalmology*. 1991;98(5):586-593.
19. Buzney SM, Frank RN, Varma SD, et al. Aldose reductase in retinal mural cells. *Investigative Ophthalmology & Visual Science*. 1977;16(5):392-396.
20. Frank RN. Etiologic mechanisms in diabetic retinopathy. In: Ryan SJ, ed. *Retina, Vol. 2: Medical Retina*. St. Louis: CV Mosby; 1989:301-326.
21. Frank RN, Keim RS, Kennedy A, Frank KW. Galactose-induced retinal capillary basement membrane thickening: prevention by sorbinil and aldose reductase inhibition. Annotated bibliography, Department of Professional Information. Pfizer Inc.; 1985.
22. Frank RN. The aldose reductase controversy. *Diabetes*. 1994;43(2):169-172.
23. Cagliero E, Maiello M, Boeri D, Roy S, Lorenzi M. Increased expression of basement membrane components in human endothelial cells cultured in high glucose. *Journal of Clinical Investigation*. 1988;82(2):735-738.
24. Ashton N. Studies of the retinal capillaries in relation to diabetic and other retinopathies. *British Journal of Ophthalmology*. 1963;47:521-538.
25. Cogan DG, Toussaint D, Kuwabara T. Retinal vascular patterns, IV: diabetic retinopathy. *Archives of Ophthalmology*. 1961;66:100-112.
26. de la Rúa G, Oliver FJ, Inoguchi T, King GL. Induction of resistance to endothelin-1's biochemical action by elevated glucose levels in retinal pericytes. *Diabetes*. 1992;41(11):1533-1539.
27. Orlidge A, D'Amore PA. Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. *Journal of Cell Biology*. 1987;105(3):1455-1462.
28. Ditzel J. Hypoxia as a pathogenic factor of microangiopathy with particular reference to diabetic retinopathy. *Acta Endocrinologica*. 1983;238(Suppl):39-55.
29. Bill A. Ocular circulation. In: Moses RA, ed. *Adler's Physiology of the Eye: Clinical Application*. 7th ed. St. Louis: CV Mosby; 1981:193-194.
30. Sullivan PM, Davies EG, Cardwell G, Morris AH, Kohner EM. Retinal blood flow during hyperglycemia. *Investigative Ophthalmology & Visual Science*. 1990;31(10):2041-2045.
31. Pierce EA, Foley ED, Smith LEH. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. *Archives of Ophthalmology*. 1996;114(10):1219-1228.
32. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. *New England Journal of Medicine*. 1994;331(22):1480-1487.
33. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, IV: diabetic macular edema. *Ophthalmology*. 1984;91(12):1464-1474.
34. Klein R, Klein BEK, Moss SE, et al. Association of ocular disease and mortality in a diabetic population. *Archives of Ophthalmology*. 1999;117(11):1487-1495.

35. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. *Ophthalmology*. 1995;102(4):647-661.
36. Vitale S, Maguire MG, Murphy RP, et al. Clinically significant macular edema in type I diabetes: incidence and risk factors. *Ophthalmology*. 1995;102(8):1170-1176.
37. Roy MS, Klein R. Macular edema and retinal hard exudates in African Americans with type 1 diabetes: the New Jersey 725. *Archives of Ophthalmology*. 2001;119(2):251-259.
38. Lopes de Faria JM, Jalkh AE, Trempe CL, et al. Diabetic macular edema: risk factors and concomitants. *Acta Ophthalmologica Scandinavica*. 1999;77(2):170-175.
39. Klein BEK, Moss SE, Klein R, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XIII: relationship of serum cholesterol to retinopathy and hard exudate. *Ophthalmology*. 1991;98(8):1261-1265.
40. Chew EY, Klein ML, Ferris FL 3rd, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy: Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. *Archives of Ophthalmology*. 1996;114(9):1079-1084.
41. Sinclair SH, Nesler C, Foxman B, et al. Macular edema and pregnancy in insulin-dependent diabetes. *American Journal of Ophthalmology*. 1984;97(2):154-167.
42. Best RM, Chakravarthy U. Diabetic retinopathy in pregnancy. *British Journal of Ophthalmology*. 1997;81(3):249-251.
43. Sunness JS. The pregnant woman's eye. *Survey of Ophthalmology*. 1988;32(4):219-238.
44. Meyers SM. Macular edema after scatter laser photocoagulation for proliferative diabetic retinopathy. *American Journal of Ophthalmology*. 1980;90(2):210-216.
45. McDonald HR, Schatz H. Macular edema following panretinal photocoagulation. *Retina*. 1985;5(1):5-10.
46. Jaffe GJ, Burton TC, Kuhn E, et al. Progression of nonproliferative diabetic retinopathy and visual outcome after extracapsular cataract extraction and intraocular lens implantation. *American Journal of Ophthalmology*. 1992;114(4):448-456.
47. Dowler JGF, Sehmi KS, Hykin PG, Hamilton AMP. The natural history of macular edema after cataract surgery in diabetes. *Ophthalmology*. 1999;106(4):663-668.
48. Aiello LM. Diagnosis, management, and treatment of nonproliferative diabetic retinopathy and macular edema. In: Albert DM, Jakobiec FA, eds. *Principles and Practice of Ophthalmology*. Philadelphia: WB Saunders; 1994:747-760.
49. Guillermo A-U, Ariadna S-L. Diabetic retinopathy. In: Agarwal S, Agarwal A, Apple DJ, Buratto L, Alió JL, Pandey SK, Agarwal A, eds. *Textbook of*

- Ophthalmology*, Vol. 4: *Retina and Vitreous, Systemic Diseases, Miscellaneous*. New Delhi: Jaypee; 2002:2560-2580.
50. Sahel JA, Brini A, Albert DM. Pathology of the retina and vitreous. In: Albert DM, Jakobiec FA, eds. *Principles and Practice of Ophthalmology*. Philadelphia: WB Saunders; 1994:2239-2280.
 51. Ashton N. Studies of the retinal capillaries in relation to diabetic and other retinopathies. *British Journal of Ophthalmology*. 1963;47:521-538.
 52. Cogan DG, Toussaint D, Kuwabara T. Retinal vascular patterns, IV: diabetic retinopathy. *Archives of Ophthalmology*. 1961;66:100-112.
 53. Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. *Diabetes*. 1987;36(7):808-812.
 54. Kohner EM, Henkind P. Correlation of fluorescein angiogram and retinal digest in diabetic retinopathy. *American Journal of Ophthalmology*. 1970;69(3):403-413.
 55. De Venecia G, Davis M, Engerman R. Clinicopathologic correlations in diabetic retinopathy, I: histology and fluorescein angiography of microaneurysms. *Archives of Ophthalmology*. 1976;94(10):1766-1773.
 56. Krupin T, Waltman SR, Szewczyk P, et al. Fluorometric studies on the blood-retinal barrier in experimental animals. *Archives of Ophthalmology*. 1982;100(4):631-634.
 57. Gillies MC, Su T, Stayt J, et al. Effect of high glucose on permeability of retinal capillary endothelium in vitro. *Investigative Ophthalmology & Visual Science*. 1997;38(3):635-641.
 58. Gardner TW, Lieth E, Khin SA, et al. Astrocytes increase barrier properties and ZO-1 expression in retinal vascular endothelial cells. *Investigative Ophthalmology & Visual Science*. 1997;38(11):2423-2427.
 59. Wallow IHL, Engerman RL. Permeability and patency of retinal blood vessels in experimental diabetes. *Investigative Ophthalmology & Visual Science*. 1977;16(5):447-461.
 60. Viores SA, Van Niel E, Swerdloff JL, Campochiaro PA. Electron microscopic immunocytochemical evidence for the mechanism of blood-retinal barrier breakdown in galactosemic rats. *Experimental Eye Research*. 1993;57(6):723-735.
 61. Begg IS, Rootman J. Clinico-pathological study of an organized plaque in exudative diabetic maculopathy. *Canadian Journal of Ophthalmology*. 1976;11(3):197-202.
 62. Sigurdsson R, Begg IS. Organised macular plaques in exudative diabetic maculopathy. *British Journal of Ophthalmology*. 1980;64(6):392-397.
 63. Bresnick GH. Diabetic maculopathy: a critical review highlighting diffuse macular edema. *Ophthalmology*. 1983;90(11):1301-1317.
 64. Tso MOM, Cunha-Vaz JG, Shih CY, Jones CW. Clinicopathologic study of blood-retinal barrier in experimental diabetes mellitus. *Archives of Ophthalmology*. 1980;98(11):2032-2040.

65. Early Treatment Diabetic Retinopathy Study Research Group. Focal photocoagulation treatment of diabetic macular edema: relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline. ETDRS Report 19. *Archives of Ophthalmology*. 1995;113(9):1144-1155.
66. Thomas AC, Aiello LM, Zagorski B. Diabetic retinopathy and diabetic macular edema. *Diabetes Care*. 2003;26(9):2653-2664.
67. Kadonosono K, Itoh N, Ohno S. Perifoveal microcirculation before and after vitrectomy for diabetic cystoid macular edema. *American Journal of Ophthalmology*. 2000;130(6):740-744.
68. Chung H, Park B, Shin HJ, Kim HC. Correlation of fundus autofluorescence with spectral-domain optical coherence tomography and vision in diabetic macular edema. *Ophthalmology*. 2012;119(5):1056-1065.
69. Kohner EM, Dollery CT, Paterson JW, Oakley NW. Arterial fluorescein studies in diabetic retinopathy. *Diabetes*. 1967;16(1):1-10.
70. Hee MR, Puliafito CA, Wong C, et al. Quantitative assessment of macular edema with optical coherence tomography. *Archives of Ophthalmology*. 1995;113(8):1019-1029.
71. Hee MR, Puliafito CA, Duker JS, et al. Topography of diabetic macular edema with optical coherence tomography. *Ophthalmology*. 1998;105(2):360-370.
72. Giovannini A, Amato G, Mariotti C, Scassellati-Sforzolini B. Optical coherence tomography findings in diabetic macular edema before and after vitrectomy. *Ophthalmic Surgery and Lasers*. 2000;31(3):187-191.
73. Otani T, Kishi S. Tomographic assessment of vitreous surgery for diabetic macular edema. *American Journal of Ophthalmology*. 2000;129(4):487-494.
74. Diabetes Control and Complications Trial Research Group. The effect of intensive diabetic treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. *Archives of Ophthalmology*. 1995;113(1):36-51.
75. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, IV: diabetic macular edema. *Ophthalmology*. 1984;91(12):1464-1474.
76. Roy MS, Klein R. Macular edema and retinal hard exudates in African Americans with type 1 diabetes: the New Jersey 725. *Archives of Ophthalmology*. 2001;119(2):251-259.
77. Lopes de Faria JM, Jalkh AE, Trempe CL, et al. Diabetic macular edema: risk factors and concomitants. *Acta Ophthalmologica Scandinavica*. 1999;77(2):170-175.
78. Chew EY, Klein ML, Ferris FL 3rd, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy: ETDRS Report 22. *Archives of Ophthalmology*. 1996;114(9):1079-1084.
79. Early Treatment Diabetic Retinopathy Study Research Group. Focal photocoagulation treatment of diabetic macular edema: relationship of treatment

- effect to fluorescein angiographic and other retinal characteristics at baseline. ETDRS Report 19. *Archives of Ophthalmology*. 1995;113(9):1144-1155.
80. Bresnick GH. Background diabetic retinopathy. In: *Retina*. Toronto: CV Mosby; 1994:1277-1318.
81. Chew EY, Klein ML, Ferris FL 3rd, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy: ETDRS Report 22. *Archives of Ophthalmology*. 1996;114(9):1079-1084.
82. Klein BEK, Klein R, Moss SE. Is serum cholesterol associated with progression of diabetic retinopathy or macular edema in persons with younger-onset diabetes of long duration? *American Journal of Ophthalmology*. 1999;128(5):652-654.
83. Davis MD, Fisher MR, Gangnon RE, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: ETDRS Report 18. *Investigative Ophthalmology & Visual Science*. 1998;39(2):233-252.
84. Browning DJ, Zhang Z, Benfield JM, Scott AQ. The effect of patient characteristics on response to focal laser treatment for diabetic macular edema. *Ophthalmology*. 1997;104(3):466-472.
85. Takagi H, Otani A, Kiryu J, Ogura Y. New surgical approach for removing massive foveal hard exudates in diabetic macular edema. *Ophthalmology*. 1999;106(2):249-256.
86. Aiello LM, Cavallerano JD, Aiello LP, Bursell SE. Diabetic retinopathy. In: *Retina, Vol. 2: Medical Retina*. Philadelphia: WB Saunders; 1999:316-344.
87. Bayraktar MZ. Diyabetik makula ödemi ve tedavisi. In: Eldem B, Aslan BS, Aydın P, Kasım R, Or M, Akata F, Can İ, Fırat E, Barlas B, eds. *Makula Hastalıkları*. Ankara: Şahin Matbaa; 2001:119-128.
88. Takagi H, Otani A, Kiryu J, Ogura Y. New surgical approach for removing massive foveal hard exudates in diabetic macular edema. *Ophthalmology*. 1999;106(2):249-256.
89. Nasrallah FP, Jalkh AE, Van Coppenolle F, et al. The role of the vitreous in diabetic macular edema. *Ophthalmology*. 1988;95(10):1335-1339.
90. Kadonosono K, Itoh N, Ohno S. Perifoveal microcirculation before and after vitrectomy for diabetic cystoid macular edema. *American Journal of Ophthalmology*. 2000;130(6):740-744.
91. Chung H, Park B, Shin HJ, Kim HC. Correlation of fundus autofluorescence with spectral-domain optical coherence tomography and vision in diabetic macular edema. *Ophthalmology*. 2012;119(5):1056-1065.
92. Pendergast SD, Hassan TS, Williams GA, et al. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. *American Journal of Ophthalmology*. 2000;130(2):178-186.
93. Lewis H, Abrams GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. *Ophthalmology*. 1992;99(5):753-759.
94. Harbour JW, Smiddy WE, Flynn HW Jr, Rubsamen PE. Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. *American Journal of Ophthalmology*. 1996;121(4):405-413.

95. Hikichi T, Fujio N, Akiba J, Azuma Y, et al. Association between the short-term natural history of diabetic macular edema and the vitreomacular relationship in type 2 diabetes mellitus. *Ophthalmology*. 1997;104(3):473-478.
96. Gandorfer A, Messmer EM, Ulbig MW, Kampik A. Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the internal limiting membrane. *Retina*. 2000;20(2):126-133.
97. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet*. 1998;352(9131):854-865.
98. Pollack JS. Overview of the use of intravitreal steroids in retinal disease. American Academy of Ophthalmology Subspecialty Day, Anaheim, CA; 2003:14-15.
99. Jonas JB, Söfker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. *American Journal of Ophthalmology*. 2001;132(3):425-427.
100. Bonini-Filho MA, Jorge R, Barbosa JC, Calucci D, Cardillo JA, Costa RA. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial. *Investigative Ophthalmology & Visual Science*. 2005;46(10):3845-3849.
101. Schindler RH, Chandler DB, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. *American Journal of Ophthalmology*. 1982;93(4):415-417.
102. Jonas JB, Kreissig I, Söfker A, Degenring RF. Intravitreal injection of triamcinolone acetonide for diabetic macular edema. *Archives of Ophthalmology*. 2003;121(1):57-61.
103. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. *Ophthalmology*. 2002;109(5):920-927.
104. Conway MD, Canakis C, Livir-Rallatos C, Peyman GA. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. *Journal of Cataract & Refractive Surgery*. 2003;29(1):27-33.
105. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, ffytche TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. *Ophthalmology*. 2001;108(4):765-772.
106. Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E. Intravitreal triamcinolone acetonide for macular edema due to central retinal vein occlusion. *British Journal of Ophthalmology*. 2002;86(2):247-248.
107. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. *Graefe's Archive for Clinical and Experimental Ophthalmology*. 2002;240(9):782-783.
108. Lewis H, Abrams GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. *Ophthalmology*. 1992;99(5):753-759.
109. Moshfeghi DM. Complications of intravitreal steroids. The Retina Debates, American Academy of Ophthalmology Subspecialty Day; 2003:65-68.

110. Tranos PG, Wickremasinghe SS, Stangos NT, Topouzis F, Tsinopoulos I, Pavesio CE. Macular edema. *Survey of Ophthalmology*. 2004;49(5):470-490.
111. Cibis GW, Abdel-Latif AA, Bron AJ, et al. *Basic and Clinical Science Course, Section 2: Fundamentals and Principles of Ophthalmology*. San Francisco: American Academy of Ophthalmology; 2003-2004.
112. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetate in exudative age-related macular degeneration. *Retina*. 2000;20(3):244-250.
113. Nelson ML, Tennant MTS, Sivalingam A, Regillo CD, Belmont JB, Martidis A. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetate injection. *Retina*. 2003;23(5):686-691.
114. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetate injection. *American Journal of Ophthalmology*. 2003;136(5):791-796.
115. Roth DB, Chieh J, Sporn MJ, Green SN, Yarian DL, Chaudhry NA. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. *Archives of Ophthalmology*. 2003;121(9):1279-1282.
116. Rodriguez-Coleman H, Yuan P, Kim H, Zurakowski D, Whitcup SM, Csaky KG. Intravitreal injection of triamcinolone for diffuse macular edema. *Archives of Ophthalmology*. 2004;122(7):1085-1086.
117. Aiello LP. The PKC-DRS Study: what happened. American Academy of Ophthalmology Subspecialty Day, Anaheim, CA; 2003:14-15.
118. Qaum T, Xu Q, Jousen AM, et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. *Investigative Ophthalmology & Visual Science*. 2001;42(10):2408-2413.
119. Das A, McGuire PG. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. *Progress in Retinal and Eye Research*. 2003;22(6):721-748.
120. Adamis AP. Looking forward: ocular biochemical warfare — the VEGF attack. American Academy of Ophthalmology Subspecialty Day, Orlando, FL; 2002:18-19.
121. Bresnick GH. Diabetic maculopathy: a critical review highlighting diffuse macular edema. *Ophthalmology*. 1983;90(11):1301-1317.
122. Bresnick GH. Diabetic macular edema: a review. *Ophthalmology*. 1986;93(7):989-997.
123. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, IV: diabetic macular edema. *Ophthalmology*. 1984;91(12):1464-1474.
124. McDonald HR, Schatz H. Grid photocoagulation for diffuse macular edema. *Retina*. 1985;5(2):65-72.
125. McCuen BW 2nd, Bessler M, Tano Y, Chandler D, Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetate. *American Journal of Ophthalmology*. 1981;91(6):785-788.

126. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. *Diabetes*. 1998;47(6):859-866.
127. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. *Ophthalmology*. 2002;109(5):920-927.
128. de Boer JF, Cense B, Park BH, Pierce MC, Tearney GJ, Bouma BE. Improved signal-to-noise ratio in spectral-domain compared with time-domain optical coherence tomography. *Optics Letters*. 2003;28(21):2067-2069.
129. Sanaka S, Yu M. Therapeutic outcomes of anti-VEGF agents versus corticosteroids in diabetic macular edema: a comparative review. *International Journal of Molecular Sciences*. 2026;27(3):1142. doi:10.3390/ijms27031142.
130. Maturi RK, Glassman AR, Liu D, et al; Diabetic Retinopathy Clinical Research (DRCR) Network. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR Network phase 2 randomized clinical trial. *JAMA Ophthalmology*. 2018;136(1):29-38. doi:10.1001/jamaophthalmol.2017.4914.
131. Faes L, Mishra AV, Lipkova V, et al. Visual and anatomical outcomes of a single intravitreal dexamethasone in diabetic macular edema: an 8-year real-world study. *Journal of Clinical Medicine*. 2023;12(12):3878. doi:10.3390/jcm12123878.
132. Wells JA, Glassman AR, Ayala AR, et al; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. *New England Journal of Medicine*. 2015;372(13):1193-1203.
133. Boyer DS, Yoon YH, Belfort R Jr, et al; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. *Ophthalmology*. 2014;121(10):1904-1914.
134. Campochiaro PA, Brown DM, Pearson A, et al; FAME Study Group. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. *Ophthalmology*. 2011;118(4):626-635.
135. Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. *Lancet*. 2022;399(10326):741-755.
136. Glassman AR, Wells JA 3rd, Josic K, et al; DRCR Retina Network. Aflibercept monotherapy or bevacizumab first for diabetic macular edema. *New England Journal of Medicine*. 2024;390(8):697-709. doi:10.1056/NEJMoa2204225.